Health Economics and Outcomes Research (HEOR)
- Evidence Planning & Study Design
- Conceptual Models
- Literature Synthesis & Meta-Analysis
- Data Sourcing, Analysis & Interpretation
- Economic Modeling, Cost Effectiveness Analysis & Budget Impact Analysis
- Web-Based Graphical Model User Interfaces
- Patient-Reported Outcomes & Utilities
- Market Access & Reimbursement
- Payer Research and Engagement
- Value Dossiers
- Peer-Reviewed Publications & Communications
- Medical device total cost of ownership (TCO) analysis
- Real-world data analysis using large datasets, including Truven, Pharmetrics, Medicare claims data, etc.
- Support to Value Analysis Teams (VAT) & Value Analysis Committees (VACs) for hospitals & health systems
- Hospital Value Analysis (HVA) of medical devices
- Clinical research monitoring and study coordination
BUSINESS ANALYTICS, LITIGATION SUPPORT & POLICY ANALYSIS
- Healthcare Management Consulting
- Data Analysis & Statistics
- Market Research
- Market Development & Expansion
- Investor Research & Analysis
- Antitrust Analysis
- Trademark infringement
- Reputational harm
- Contractual Disputes & Payer-Provider Disputes
- Review & Analysis of Medical Claims & Bills
- Reasonable Value of Medical Losses
- Policy Research
- Cost-Benefit Analysis & Cost-Impact Analysis
- Data Analytics & Simulation Modelling
- International Health
Read more:
Spotlight
- Analysis of Dental and Vision Plan Non-Covered Services and Materials Mandates and the Projected Role of H.R. 3323 in the Vision and Dental Markets
- Medical Device Economics and the Health System Purchaser in the Era of Novel Payment Mechanisms
- Value-Based Payment for Oncology Services
- Why Medical Device Companies Need to Develop Economic Evidence in the U.S.
- Avalon CEO John Schneider presented at BMO Capital Markets' "The Year Ahead in Healthcare: Products, Payment and Politics" on December 15, 2015
- Philipp Schuetz joins Avalon Health Economics as a Clinical Director
- CEO John Schneider presents at Barclays HealthCare Symposium
- Reference Pricing for in vivo and in vitro Diagnostic Tests
- Julian Nam and Wenjia Chen join Avalon as health economists
'